FDA preps for DMD drug generics as Sarepta has yet to finish its confirmatory trial

The FDA typically releases guidance to help generic drug manufacturers develop new copycats of small molecule drugs, oftentimes in preparation for a brand name product’s patents or exclusivity to expire.